The most anticipated and controversial moment in longevity biology has just moved from the laboratory to actual patients; for the first time in medical history, a human being has received an experimental gene therapy designed to revert aging eye cells to a more youthful state. Here, we examine the molecular engineering behind the compound ER-100, the Harvard-inspired studies, and the risks that divide the scientific community—balancing the promise of a miracle against the fear of unleashing something far more dangerous.
In other words, the body might still possess a hidden biological backup, making it possible to restore some of these instructions so that aging tissues regain lost functions; to put this idea into practice, engineers at Life Biosciences developed an extremely sophisticated control system. ER-100 uses a modified, harmless virus as a delivery vehicle.
Posted Using INLEO
